Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 88

Similar articles for PubMed (Select 23943468)


Improved neurocognitive test performance in both arms of the SMART study: impact of practice effect.

Grund B, Wright EJ, Brew BJ, Price RW, Roediger MP, Bain MP, Hoy JF, Shlay JC, Vjecha MJ, Robertson KR; INSIGHT SMART Study Group.

J Neurovirol. 2013 Aug;19(4):383-92. doi: 10.1007/s13365-013-0190-x. Epub 2013 Aug 14.


Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons.

Wright EJ, Grund B, Robertson K, Brew BJ, Roediger M, Bain MP, Drummond F, Vjecha MJ, Hoy J, Miller C, Penalva de Oliveira AC, Pumpradit W, Shlay JC, El-Sadr W, Price RW; INSIGHT SMART Study Group.

Neurology. 2010 Sep 7;75(10):864-73. doi: 10.1212/WNL.0b013e3181f11bd8. Epub 2010 Aug 11.


Factors associated with neurocognitive test performance at baseline: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

Wright EJ, Grund B, Cysique LA, Robertson KR, Brew BJ, Collins G, Shlay JC, Winston A, Read TR, Price RW; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group.

HIV Med. 2015 Apr;16 Suppl 1:97-108. doi: 10.1111/hiv.12238.


Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort.

Robertson KR, Su Z, Margolis DM, Krambrink A, Havlir DV, Evans S, Skiest DJ; A5170 Study Team.

Neurology. 2010 Apr 20;74(16):1260-6. doi: 10.1212/WNL.0b013e3181d9ed09. Epub 2010 Mar 17.


Longitudinal neuropsychological test performance among HIV seropositive individuals in Uganda.

Sacktor N, Nakasujja N, Okonkwo O, Skolasky RL, Robertson K, Musisi S, Katabira E.

J Neurovirol. 2013 Feb;19(1):48-56. doi: 10.1007/s13365-012-0139-5. Epub 2013 Jan 12.


Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study.

Ananworanich J, Siangphoe U, Hill A, Cardiello P, Apateerapong W, Hirschel B, Mahanontharit A, Ubolyam S, Cooper D, Phanuphak P, Ruxrungtham K.

J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):523-9.


Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).

Vogler MA, Teppler H, Gelman R, Valentine F, Lederman MM, Pomerantz RJ, Pollard RB, Cherng DW, Gonzalez CJ, Squires KE, Frank I, Mildvan D, Mahon LF, Schock B; AIDS Clinical Trials Group 248 Study Team.

J Acquir Immune Defic Syndr. 2004 May 1;36(1):576-87.


Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders?

Vassallo M, Durant J, Biscay V, Lebrun-Frenay C, Dunais B, Laffon M, Harvey-Langton A, Cottalorda J, Ticchioni M, Carsenti H, Pradier C, Dellamonica P.

AIDS. 2014 Feb 20;28(4):493-501. doi: 10.1097/QAD.0000000000000096.


Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment.

Heseltine PN, Goodkin K, Atkinson JH, Vitiello B, Rochon J, Heaton RK, Eaton EM, Wilkie FL, Sobel E, Brown SJ, Feaster D, Schneider L, Goldschmidts WL, Stover ES.

Arch Neurol. 1998 Jan;55(1):41-51.


Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART body composition substudy.

Hoy J, Grund B, Roediger M, Ensrud KE, Brar I, Colebunders R, Castro ND, Johnson M, Sharma A, Carr A; INSIGHT SMART Body Composition Substudy Group.

J Bone Miner Res. 2013 Jun;28(6):1264-74. doi: 10.1002/jbmr.1861.


Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIV-infected patients responding to highly active antiretroviral therapy.

Giancola ML, Lorenzini P, Balestra P, Larussa D, Baldini F, Corpolongo A, Narciso P, Bellagamba R, Tozzi V, Antinori A.

J Acquir Immune Defic Syndr. 2006 Mar;41(3):332-7.


The effect of opportunistic illness on HIV RNA viral load and CD4+ T cell count among HIV-positive adults taking antiretroviral therapy.

Ekwaru JP, Campbell J, Malamba S, Moore DM, Were W, Mermin J.

J Int AIDS Soc. 2013 Apr 1;16:17355. doi: 10.7448/IAS.16.1.17355.


CD4+ count-guided interruption of antiretroviral treatment.

Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fätkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C.

N Engl J Med. 2006 Nov 30;355(22):2283-96.


The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters.

Martinez E, Visnegarwala F, Grund B, Thomas A, Gibert C, Shlay J, Drummond F, Pearce D, Edwards S, Reiss P, El-Sadr W, Carr A; INSIGHT SMART study group.

AIDS. 2010 Jan 28;24(3):353-63. doi: 10.1097/QAD.0b013e3283333666.


Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.


Screening for HIV-associated dementia in South Africa: potentials and pitfalls of task-shifting.

Robbins RN, Remien RH, Mellins CA, Joska JA, Stein DJ.

AIDS Patient Care STDS. 2011 Oct;25(10):587-93. doi: 10.1089/apc.2011.0154. Epub 2011 Sep 15.


Neurodevelopmental delay among HIV-infected preschool children receiving antiretroviral therapy and healthy preschool children in Soweto, South Africa.

Lowick S, Sawry S, Meyers T.

Psychol Health Med. 2012;17(5):599-610. doi: 10.1080/13548506.2011.648201. Epub 2012 Feb 7.


Evidence for extended age dependent maternal immunity in infected children: mother to child transmission of HIV infection and potential interventions including sulfatides of the human fetal adnexa and complementary or alternative medicines.

Bhargav H, Huilgol V, Metri K, Sundell IB, Tripathi S, Ramagouda N, Jadhav M, Raghuram N, Ramarao NH, Koka PS.

J Stem Cells. 2012;7(3):127-53. doi: jsc.2012.7.3.127.


An optimal body mass index range associated with improved immune reconstitution among HIV-infected adults initiating antiretroviral therapy.

Koethe JR, Jenkins CA, Shepherd BE, Stinnette SE, Sterling TR.

Clin Infect Dis. 2011 Nov;53(9):952-60. doi: 10.1093/cid/cir606. Epub 2011 Sep 26.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk